2954-4122

S2954-41222025000200079

10.24875/anc.25000003

México

00 06 2025

30 2 79 103

2002 16 10 10

669-94

1963 18

435-8

1964 122

577-85

1980 30 1 1

1-6

2003 9 2 2

199-216

2010 65 3 3

233-40

2002 16 10 10

695-714

2023 20 2 2

2376

2013 20 8 8

1079-82

2013 84 10 10

1138-47

2018 55

17-24

2007 75 (2-3) (2-3)

122-9

2021 25 75 75

1-134

2022 12 1 1

36-8

2018 43 4 4

571-3

2000 58 (3A) (3A)

683-90

2006 67 10 10

1872-5

2013 20 8 8

1079-82

2004 19 2 2

135-41

2009 14 4 4

610-6

2018 139

20-7

2016 6 6 6

2016 46 5 5

601-2

1994 49 8 8

573-5

2020

2017 92 10 10

1491-8

The RAND/UCLA Appropriateness Method User's Manual [Internet]

2021 9 4 4

194

2017 58 4 4

522-30

2007 90 9 9

1809-14

2009 50 6 6

1517-24

2022 98 21 21

894-5

2024 56 1 1

61-3

2015 56 8 8

1185-97

2022 15

809951

2020 10 4 4

344-55

2008 49 7 7

1239-76

2021 20 2 2

215-23

2023 39 1 1

314

2020 4 4 4

CD007286

2014 (10)

CD010247

2022 17 3 3

2023 149

109499

2022 21 4 4

316-25

2007 22 1 1

15-20

2021 91

159-66

1991 9 4 4

317-21

2021 25 75 75

1-134

2018 19 8 8

843-50

2002 50 3 3

243-9

2009 111 5 5

437-41

2004 63 8 8

1507-8

2007 48 3 3

478-83

2008 118 5 5

296-300

2005 46 6 6

949-51

2024 21 3 3

2022 233

108026

2002 33 4 4

174-7

2023 45 8 8

451-5

2021 60 22 22

3621-4

2015 56 11 11

175

2002 51 10 10

1274-8

2011 20 2 2

146-53

2011 20 9 9

964-71

2011 20 1 1

80-2

2018 73 3 3

826-7

2012 13 5 5

291-6

1990 149 5 5

363-4

1993 22 2 2

341-4

2009 47 7 7

609-16

2006 67 (12 Suppl 4) (12 Suppl 4)

S28-33

2005 33 3 3

311-22

2005 66 1-3 1-3

173-83

2022 63 2 2

259-70

2015 30 1 1

63-8

2011 20 6 6

500-1

1989 48 3 3

542

2006 184

28-37

2003 23 5 5

471-8

2020 161

106297

2019 119 2 2

163-73

2016 16 1 1

149

2022 37 3 3

171-7

2017 73

71-6

2011 52 12 12

2203-8

2010 58 3 3

465-71

2017 88 10 10

1197-207

2024 199

107282

2020 112

107400

2009 49 Suppl 1 Suppl 1

113-8

2019 119 2 2

163-73

2019 60 11 11

2245-54

2021 118

107928

2009 73 2 2

126-32

2016 7

69-76

2021 119

107980

2018 2018 12 12

CD013225

2020 113

107563

2002 52 6 6

704-11

100

Research C for DE and FDA Drug Safety Communication:valproate anti-seizure products contraindicated for migraine prevention in pregnant women due to decreased IQ scores in exposed children [Internet]

101

2023 64 4 4

910-8

102

2008 81 1 1

1-13

103

2024 102 11 11

104

2013 309 16 16

1696-703

105

2024 390 12 12

1069-79

106

2023 35 2 2

87-93

107

2019 21 6 6

497-517

108

2021 11 2 2

109

2013 80 6 6

590-9

110

2017 58 6 6

973-82

111

2018 89

70-8

112

2014 14

113

2017 58 7 7

1268-76

114

2019 26 6 6

856-64

115

2017 88 11 11

933-40

116

2014 133 6 6

1593

117

2008 22 1 1

27-47

118

2000 33 5 5

182-8

119

2004 56 11 11

868-74

120

2003 49 6 6

1595-603

121

2017 20 2 2

121-79

122

2018 20 2 2

97-170

123

2022 27 2 2

1136-44

124

2021 26 8 8

4146-57

125

2014 2014 2 2

CD008544

126

2006 29 6 6

350-60

127

2007 62 4 4

345-54

128

2016 77 5 5

579

129

2018 667

27-39

130

2024 22 2 2

260-89

131

2018 78

68-72

132

2018 75 6 6

663-71

133

2018 9

270

134

2012 17 (1 Suppl) (1 Suppl)

94-101